IGC Pharma, Inc. (IGC) Stock Analysis & Investment Frameworks
IGC Pharma, Inc. (IGC) stock analysis on Invetso. Review IGC Pharma, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
IGC Pharma, Inc. Company Overview
- Exchange: New York Stock Exchange Arca
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
IGC Pharma, Inc. Key Financial Metrics
- Market Cap: $25.43M
- Revenue: $1.19M
- ROE: -113.58%
- ROIC: -153.62%
- Dividend Yield: N/A
About IGC Pharma, Inc.
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
IGC Pharma, Inc. Investment Frameworks
Invetso analyzes IGC Pharma, Inc. (IGC) across the following frameworks:
- IGC Pharma, Inc. 10Y Growth Potential
- IGC Pharma, Inc. Scenario Analysis
- IGC Pharma, Inc. Risks & Opportunities
- IGC Pharma, Inc. Economic Moat
- IGC Pharma, Inc. Business Model
- IGC Pharma, Inc. Management
- IGC Pharma, Inc. SWOT Analysis
- IGC Pharma, Inc. Porter's 5 Forces
- IGC Pharma, Inc. PESTLE Analysis
- IGC Pharma, Inc. ESG Analysis